• SRAX Inc. reported its 2Q2020 results on August 17, 2020
• Company reported revenues of $1.1 million, up 29% YoY with EBITDA rising by 35% YoY
• SRAX has been diligently implementing cost-savings measures, with operating cost reduction of 21% QoQ and 39% YoY
• Company has sought to bolster balance sheet, closing convertible debt offering of $16.1 million during quarter
• SRAX announced its acquisition of nearly $5 million in bookings across Sequire, BIGtoken platforms over the first six weeks of third quarter

SRAX (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, recently reported its results for the second quarter ending June 30, 2020. Despite a largely tumultuous quarter marked with widespread lockdowns amidst the COVID-19 virus, SRAX reported revenues up 29% year-over-year accompanied by a significant expansion in gross margins, driving quarterly EBITDA up 35% year-over-year (http://ibn.fm/6l8wW). The results were a testament to SRAX’s diversified product portfolio, as extraordinary performance by the company’s investor intelligence platform, Sequire was matched by strong growth witnessed within its BIGtoken platform.

In addition to SRAX’s robust revenue and earnings growth, the company has continued making strides in lowering its overall expense profile, which saw operating expenses decline by 21% relative to the same period last year. SRAX has also worked towards bolstering its balance sheet strength by recently announcing the close of a $16.1 million convertible debt offering, putting the company in a strong cash position to accommodate future growth.

Sequire, SRAX’s SAAS investor intelligence platform, was only rebranded as such towards the end of the first quarter but has already garnered great popularity – with over 1 million investors and traders currently on its platform. Separately, the Company also revealed that Sequire had now seen 91 publicly listed companies subscribe to its platform, a remarkable 54% increase relative to the number of corporate subscribers at the end of 2019 – an explosion of growth largely driven by Sequire’s extensive range of services.

The Company’s management illustrated the platform’s potential by outlining one example, where a single corporate subscriber using Sequire has seen their number of individual shareholders skyrocket—from 3,000 to over 360,000 during their tenure on the platform. The trend has now led the Sequire SAAS platform to record six consecutive quarters of growth.

“The growth we experienced this last quarter and through today has been the fastest growth we have encountered as a public company. For the past six weeks we have closed close to $1M per week in business, mostly driven by our Sequire platform,” said SRAX CEO and founder Christopher Miglino. “Public issuers are seeing the benefits of the platform, and our data teams are gaining significant insights from that growth. Sequire now has over 1 million investors and traders, a significant portion of which are from the Robinhood platform.”

The positive growth within the Sequire business has been mirrored by SRAX’s BIGtoken platform, which has seen a number of advertisers sign up to gain access to the verified consumer insights provided by BIGtoken’s over 16.7 million users. SRAX revealed that they witnessed the likes of lottery.com, Singapore’s GroupM and consumer product giant Procter & Gamble sign up as clients over the course of the quarter with corporate advertisers increasingly looking to gain access to verified consumer data, which in turn could help them better reach and serve their audiences.

Impressively, the positive trend seems to have carried on, as Miglino revealed that the company had booked close to $5 million in sales between BIGtoken and Sequire over the first six weeks of the third quarter – a huge outperformance given that the company had earlier forecast $3 million in sales for the entire quarter, a target exceeded over the month of July alone.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Kingman Minerals’ assets include both the Mohave Project as well as Quebec, Canada-based Cadillac East Property
• Cadillac East Property is situated within Abitibi Greenstone Belt, Canada’s most prolific gold mining zone and home to region’s largest open-pit gold mine, Canadian Malartic Mine
• In 2014, junior mining company that discovered Canadian Malartic Mine in 2011 went on to sell its interests in asset for gross consideration of $3.9 billion
• Though Kingman Minerals’ near-term potential lays firmly within confines of the Arizona-based Mohave Project, its interest within the Cadillac East project should not be disregarded

Kingman Minerals (TSX.V: KGS), a Canada-listed gold miner with extensive claims in key mining jurisdictions spanning the North American continent, has featured prominently in recent weeks due to its extensive mining interests within the Music Mountains in Mohave County, Arizona – a territory encompassing 72 lode claims and spanning nearly 1,500 acres. However, Kingman Minerals has recently sought to expand its geological footprint across the North American continent, acquiring the mining interests within the Cadillac East property, a stretch of land totaling 691.07 hectares and encircling 12 claims within its boundaries (http://ibn.fm/ITm3U).

The Cadillac East Property is situated approximately 55 kilometers east of the city of Val d’Or in the Province of Quebec and 500 kilometers north-west of the city of Montreal. Located within the Abitibi Greenstone Belt, the Cadillac East property is positioned within one of Canada’s most prolific mining zones which has seen exploration activity take place dating back to the 1940’s. Today, the Abitibi Greenstone Belt and the Val d’Or region play host to the Canadian Malartic gold mine, the largest open-pit gold mine in Canada with total deposits estimated at close to 10 million ounces of gold (http://ibn.fm/jJi6z).

Located only a few kilometers away from Kingman Minerals’ Cadillac East property, the Malartic mine possesses the ability to process over 57,000 tons of ore a day and produced a total of 662,918 ounces of gold and over 800,000 ounces of silver in 2019 alone. Notably, to illustrate the potential monetization of such mining sites – while the Canadian Malartic mine is currently jointly-owned and operated by Agnico East and Yamana Gold, it was originally discovered in 2011 by Osisko Mining Corporation – a then-junior mining company which went on to sell its mining asset to its current owners for a total consideration of $3.9 billion in 2014 (http://ibn.fm/Gl90h).

In 2017, exploration work carried out by Exploration Facilitation Unlimited Inc. within the boundaries of the Cadillac East property identified a number of potential targets for further investigation. Initial findings from the exploration program found gold values ranging from 1 to 59 parts per billion (“ppb”) and silver values ranging from 0.15 to 5.2 parts per million (“ppm”), where any concentration of gold above 4 ppb is considered to be anomalous and deemed worthy of further exploration.

Despite the promising results found during the initial exploration of the Cadillac East site, Kingman Minerals has opted to prioritize its ongoing drill campaign aimed towards confirming the viable ore deposits within its Arizona-based Mohave Project, which is expected to be delivered in the near future.  The Mohave site was previously studied in 1985 by L.A. Bayrock Ph.D P.Geo (“Bayrock) on behalf of Stellar Resource Corp. Although the study was carried out prior to the current NI 43-101 regulations coming into force, Stellar Resource’s report at the time suggested that the mine’s potential assets could amount to as much as 664,000 ounces of gold and 2,600,000 ounces of silver (http://ibn.fm/JB7FN).

With gold prices rising above the historic $2,000/oz threshold in August 2020, Kingman Minerals is well positioned to capitalize upon the favorable gold environment. While it is currently working on producing its NI 43-101 compliant report on the proven and probable gold reserves contained within its Mohave Project site, its yet untouched Cadillac East property should not be overlooked for its potential.

For more information, visit the company’s website at www.KingmanMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to KGS are available in the company’s newsroom at http://ibn.fm/KGS

• NETE, Mullen Technologies sign definitive merger agreement
• Newly formed company will be dedicated to development of environmentally friendly, affordable technology offering energy solutions
• Agreement calls for Net Element’s wholly owned, newly formed subsidiary to acquire all outstanding shares of Mullen

Net Element (NASDAQ: NETE), a global financial technology and value-added solutions group, has signed a definitive merger agreement with Mullen Technologies Inc. The agreement outlines a stock-for-stock reverse merger plan resulting in Mullen, a privately held electric vehicle company, and its stockholders owning a majority of the outstanding stock in the post-merger company (http://ibn.fm/5LwBp).

“We are excited to move forward with the proposed merger with Mullen Technologies,” said Net Element executive chairman Oleg Firer. “We are confident that this transaction will increase shareholder value in the long term.”

The details of the newly inked merger agreement call for Net Element’s wholly owned, newly formed subsidiary to acquire all outstanding shares of Mullen. Once the merger is complete, Net Element shareholders will own 15% and Mullen shareholders will own 85% of the issued and outstanding shares of the combined company. The agreement also dictates that Net Element has the right to acquire up to an additional 6.7% of the combined company dependent on the amount of loans from Net Element to Mullen prior to closing.

In addition, the agreement notes that, just prior to the completion of the merger, Net Element will divest itself of its payments-processing business and portfolio, pending approval of the company’s stockholders. The completion of the merger itself is also subject to shareholder and NASDAQ approval, as well as other conditions outlined in the agreement.

Based in Southern California, Mullen Technologies is a licensed electric vehicle company with international distribution that operates in a variety of businesses focused on the automotive industry, including Mullen Automotive, Mullen Energy, Mullen Auto Sales, Mullen Funding Corp. and CarHub.

“Our team at Mullen Technologies is very proud to take the next step in completing this acquisition of Net Element,” said Mullen founder and CEO David Michery. “Mullen is dedicated to the development of environmentally friendly, affordable technology that will bring energy solutions to consumer products and communities in the near future. This acquisition provides the resources that Mullen can utilize to execute on its business model to integrate state-of-the-art, clean-battery technology into personal and commercial vehicles, and eventually sustainable, reusable battery technology into everyday consumer products.”

Net Element Inc. is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• Company’s commercial VOD technology designed to provide increasing revenues
• MVES’s direct-server access platform offers variety of entertainment for worldwide distribution
• The Movie Studio has expertise, reputation to be both leader, pioneer in VOD space

In a dynamic and growing industry, The Movie Studio (OTC: MVES), a vertically integrated motion picture production and distribution company, differentiates itself from other providers of streamed content in a variety of ways, including a commercial video on demand (“VOD”) technology that offers efficiency and is designed to provide increasing overall revenues for all parties involved in the motion picture production and distribution channels (http://ibn.fm/kLmlH).

Committed to its slogan — ‘Changing the way the world views movies’ — The Movie Studio and its distinctive business model breaks away from the traditional physical copy distribution format of files, eliminating piracy, revenue loss from copying and video manipulation. The company’s strategic plan includes motion picture aggregation and distribution intended to create a direct server access platform offering its both its own and aggregated feature film, television programming and other media to “geo-fractured” territories for worldwide distribution.

MVES has also created a platform designed to eliminate the theft of content and grow income potential for everyone involved in the production and distribution of its content. In addition, the company looks for other ways to distinguish itself in the space, including managing its own in-house marketing and distribution department.

With a four-decade legacy and tradition — the company was founded in 1961 and is the only major independent studio based in Florida — The Movie Studio has the expertise and reputation to be both a leader and a pioneer in the VOD and other related spaces. The company was the first to create a first mover digital disruptor focused on the independent motion picture content sector and is intent on changing the way independent motion pictures are made and distributed.

Part of that plan involves developing, manufacturing, and distributing its own motion picture content for worldwide consumption. The Movie Studio uses a variety of high-definition cameras, including the RED camera used in filming parts of the blockbuster “Jurassic World” and other major Hollywood movies. The company’s unique production plans involve filming its projects in 10 “chapters” and then editing those chapters together to create a completed film. These chapters, or moviesodes, are released via The Movie Studio’s own app, which is available in the Apple App Store and the Google Play Store. This unique approach creates a stickiness to the app as well as recurring revenue for the company and all involved in production.

The company currently has three films in production: “Cause and Effect,” a Miami street movie about the seedy underbelly of South Florida nightlife; “The Last Warhead,” an adventure film where fantasy meets reality; and “PEGASUS,” a family movie about a young girl and a horse which MVES plan to make its “signature” film.

The Movie Studio is a vertically integrated, motion-picture production and distribution company engaged in the acquisition, development, production and distribution of independent motion-picture content for worldwide consumption, with a particular focus on video on demand (“VOD”), foreign sales and various media devices.

For more information about the company, visit www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

• ISWH is “ramping up” with compelling ties to both crypto and telehealth, as well as yearlong strong financials
• Company’s Q2 2020 numbers report sales up 79%, set to double 2019 revenues
• Recent article notes that ISWH is in the “driver’s seat”

ISW Holdings (OTC: ISWH), a brand-management portfolio company, is “doing good by doing well right now,” reports a recent “Journal Transcript” article (http://ibn.fm/AxMav). The article notes that ISWH is “a company ramping up with a tie-in of crypto and telehealth that is extremely compelling, especially given its strong run of financial performance over the past year.”

In ISW Holdings’ most recent financial report — its Q2 2020 numbers — the company announced that sales were up 79% and that numbers were on pace to double 2019 revenues (http://ibn.fm/9neEp). In addition, the company is developing a new TeleCare telehealth solution for integration into its Paradigm Home Healthcare (“PPH”) division and has signed a new joint venture agreement with Bit5ive LLC to deliver its 1 MW cryptocurrency mining turnkey solution to a major Pennsylvania mining facility.

“To say that ISWH may be undervalued seems like an understatement fit for a contest,” the “Journal Transcript” article stated. “The company has regularly posted sequential quarterly top-line growth numbers in the double-digit space. And, based on its most recent press release, this streak is set to continue. . . .  ISW Holdings just reported that it anticipates continued improvement and sequential quarterly revenue growth when performance data for quarter-ended June 30 are disclosed this month.”

The company’s growth comes primarily from its involvement in two spaces: telehealth and crypto mining. The company’s most recent success can be tied to its strong movement forward by PPH. “Make no mistake about it, home healthcare is the future of healthcare,” noted the “Journal Transcript” article. “The revolution has been brewing for years. Healthcare is too expensive, and technology now allows us to accomplish terrific healthcare without being hooked up to machines in a hospital bed 24/7 anymore. We can manage this with more finesse and ingenuity at this point.”

In the crypto world, ISWH has completed design-stage work on its 1MW Proceso S19 Pod5ive Data Center designed for shipment to the 100-megawatt Pennsylvania cryptocurrency mining project as part of its joint venture with Bit5ive LLC.

“That puts ISWH in the drivers’ seat as the crypto cycle takes flight once again,” the article notes. “Bitcoin has taken flight in the past few weeks along with gold and silver as the U.S. dollar has dumped into the gutter on a number of factors, including poor management of the virus as well as a ton of fresh signals on money supply growth via the Fed and the U.S. Congress.”

Based in Nevada, ISW Holdings is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development and early-growth facilitation, as well as brand identity through its proprietary procurement process. Together with its partners, ISWH seeks to provide a structure that meets large scalability demands as well as anticipated marketplace needs. ISWH maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

For more information about ISW Holdings, please visit the company’s website at www.ISWHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• Canada’s Minister of Health approves the use of psilocybin therapy in end-of-life care of four Canadians battling incurable cancer
• The Decision marks first legal, medical exemptions for psilocybin use in Canada since the compound became illegal in 1974
• Cybin subsidiary Serenity Life Sciences focuses on advancing R&D of psilocybin-based pharmaceutical products

A ground-breaking decision by Canada’s Minister of Health, the Honourable Patty Hajdu, to approve the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU) bodes well for companies such as Cybin Corp., which are operating in the psilocybin sector. An exemplary Canada-based, life-sciences company, Cybin focuses on developing pharmaceutical-grade psilocybin products. Therefore, the company appears ideally positioned to leverage this milestone moment.

The four applicants received the first known legal, medical exemptions for psilocybin use in Canada since the compound became illegal in the country in 1974.

“I want to thank the Health Minister and Health Canada for approving my request for psilocybin use,” said Laurie Brooks, one of the applicants. “The acknowledgment of the pain and anxiety that I have been suffering with means a lot to me, and I am feeling quite emotional . . . as a result. I hope this is just the beginning and that soon all Canadians will be able to access psilocybin, for therapeutic use, to help with the pain they are experiencing, without having to petition the government for months to gain permission.”

Application for exemptions were made with the assistance of TheraPsil, a nonprofit coalition that advocates for legal, compassionate access to psilocybin therapy for Canadians in palliative care. In the press release following the announcement of the approval, TheraPsil noted that it is “anticipated that there will now be many more applications made through the exemption process provided under the Canadian Drugs and Substances Act.”

Cybin is keenly interested in this decision, as well as the subsequent anticipated increased interest in psilocybin therapy. The company, which operates in the functional-mushroom market, intends to develop fungi-derived medicinal products, via Serenity Life Sciences. The wholly owned subsidiary focuses on advancing research and development of psilocybin-based pharmaceutical products.

“This is a watershed moment for the patients involved who deserve the right to manage their health challenges with dignity,” said Cybin co-founder Paul Glavine (http://ibn.fm/Jtrkp). “Everyone at Cybin applauds the efforts of TheraPsil and these brave individuals, and we thank the Minister of Health for her foresight.”

Former Ontario Health Minister and Cybin advisor Dr. Eric Hoskins praised Hajdu’s approval. “I am pleased to see this important step towards considering psilocybin as a natural compound with a growing body of experience of therapeutic uses for patients in need, rather than strictly a prohibited substance. I joined Cybin because of their dedication to patients who need and benefit from psilocybin-assisted therapy,” he said.

“This landmark recognition of the benefits of psilocybin is tremendous validation for our sector,” said Cybin Chief Medical Officer Dr. Jukka Karjalainen, who also noted that Cybin is proud to applaud TheraPsil’s efforts. Cybin is currently focusing on developing a psilocybin oral film delivery system that will potentially alleviate the burden of pill consumption for seniors and patients in palliative care, who often have difficulty swallowing.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

• DarioHealth Corp. reported its second quarter financial results Aug. 12, showing a revenue increase on a quarter-to-quarter basis, as well as gross profit increases of 95 percent and 60 percent on year-over-year quarterly and six-month measures, respectively
• CEO Erez Raphael recently appeared on Fox Business news forum “The Claman Countdown” to discuss the company’s health and the state of the telemedicine industry amid reports of high-value M&A activity
• Telemedicine has gained significant popularity as a means of maintaining health standards while reducing or eliminating the risk of virus transmission during the ongoing COVID-19 pandemic
• U.S. President Donald Trump recently signed measures designed to make emergency authorization for insurance reimbursements for telehealth services more permanent beyond the duration of the pandemic, and many private insurers are beginning to follow suit
• DarioHealth has gained market attention as it has racked up successes in advancing its remote health monitoring platform for diabetes and hypertension patients where it is commercially available in the United States, Canada, the United Kingdom, Europe and Australia after clearing regulatory hurdles
• The company announced its first two remote patient monitoring agreements in North America in June, followed by an agreement covering the United Kingdom and Ireland in July

The innovative energy driving the health technology company DarioHealth (NASDAQ: DRIO) has generated a series of successes for the small-cap company, and DarioHealth is anticipating additional developments in the coming weeks that may help the company continue to grow and mature, according to CEO Erez Raphael in the company’s just-released Q2 financial statement. “The COVID-19 pandemic has accelerated our ongoing transformation to a business-to-business-to-consumer (B2B2C) digital therapeutics leader,” Raphael stated in the Aug. 12 statement (http://ibn.fm/clts7). “We advanced late-stage discussions with health plans and self-insured employers, who we believe recognize how our industry-leading user engagement and satisfaction metrics lead to improved health for their member and employee populations. … We believe that we are poised to announce new and potentially transformational agreements in the next few weeks.” DarioHealth recorded a 7.2 percent sequential increase in revenues from the first to second quarter and a 95 percent year-over-year increase in quarterly gross profit due principally to an increase in membership revenues and a decrease in product costs during the second quarter, according to the financial report. On a six-month reporting measure, the company saw revenues decrease 11.3 percent year-over-year as part of its transformation from a direct-to-consumer operation, but gross profits increased by 60 percent as a result of the same processes, resulting in $1.4 million in added profits for the first half of 2020. Fox Business news forum “The Claman Countdown” recognized DarioHealth’s growing success in an Aug. 7 segment that featured Raphael’s perspective about M&A activity within the telemedicine sector and DarioHealth’s strong trending in the marketplace at the time (http://ibn.fm/hWIOl). “We are in a very, very special period of time when we see a huge transformation of the space,” Raphael told interviewer Liz Claman. Raphael added that DarioHealth has been “part of the digital health and digital therapeutics (sector) for the last 10 years and we have been there for a long time building very smart technologies, and I can tell you the last five months are big in terms of the transformation that we feel. A lot of bills that we were trying to get for a lot of fields of science, we feel we are getting there and this is a very good signal from the White House that understands the importance of virtualization of the health care industry.” DarioHealth’s CEO was responding to news that U.S. President Donald Trump had signed an executive order directing Centers for Medicare and Medicaid Services (“CMS”) officials to make some emergency telehealth regulatory reforms permanent so that they will remain in place even beyond the pandemic, although keeping some other emergency measures in place, such as enabling patients to get coverage for telehealth visits at home, will require Congressional approval (http://ibn.fm/0RdQa). The use of telemedicine services has surged during the COVID-19 pandemic as patients and medical providers have worked to maintain standard of health services through remote, virtual platforms to minimize the risk of spreading infection. Medicare’s fee-for-service telehealth claims rose from 13,000 per week before the pandemic to nearly 1.7 million by the end of April, and claims to private insurers have grown 4,347 percent year-over-year (http://ibn.fm/UbzRt). Trump’s executive action also directed the Department of Health and Human Services (“HHS”) to begin a payment program designed to make government healthcare program reimbursements more consistent to rural community hospitals as they demonstrate quality care, and directed the Departments of Agriculture (“USDA”), HHS and the Federal Communications Commission (“FCC”) to form a task force designed to improve broadband infrastructure in rural communities for telehealth providers. “Today I’m taking action to ensure telehealth is here to stay,” Trump said in announcing the orders. DarioHealth’s CEO noted that insurance companies in the private sector are also moving to adopt such measures, building a framework by which telehealth services can be recognized as vital and quality-focused so that providers and patients may utilize technological tools under a rubric that authorizes reimbursements. DarioHealth’s Remote Patient Monitoring (“RPM”) digital therapeutics platform transmits patient information to physicians and also delivers occasional “nudges” to patients when its automated programming recognizes a need (http://ibn.fm/aH4UZ). The RPM is specifically designed for diabetes and hypertension patients, with the potential for monitoring and helping to manage a wide array of chronic conditions in the future. The company’s blood glucose monitoring system has U.S Food and Drug Administration (“FDA”) clearance and has similarly been approved by European, Canadian and Australian regulatory agencies that have allowed it to become commercially available in the United States, Canada, the United Kingdom and Ireland, Germany, Italy, and Australia while continuing to expand into new geographic markets and to support additional chronic conditions. For more information, visit the company’s website at www.DarioHealth.com. NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

• Vast potential of mushroom medicine market is hindered by lack of pharma-grade extracts preventing brands from seizing this market opportunity
• Traditional extract producers limited by low-volume, non-scalable manufacturing methods
• Pure Extracts equipped to produce urgently needed pharma-grade psilocybin

Pure Extracts, a Canadian plant-based extraction company operating in the functional medicinal mushrooms space, is in a unique position to become the dominant extraction company and a leader in the rapid development and commercialization of functional medicine products. With its substantial experience and technical competence in plant extraction creating a distinctive competitive advantage, Pure Extracts is focused on becoming a critical partner with companies developing powerful mushroom products.

As a growing body of research substantiates that psilocybin offers benefits in the treatment of depression, PTSD, anxiety, bi-polar, drug and alcohol addiction, obesity, narcolepsy, OCD, Alzheimer’s and ADHD, an increasing number of companies are looking into expanding into this space to develop products to treat these conditions (http://ibn.fm/oxiSy). However, those companies lack the high purity psilocybin compounds required for the requisite clinical trials and research needed to harness the power of this global market.

Few companies in the extraction space can deliver on this urgent need. Most providers in the space are unable to develop pharmaceutical-grade compounds because their manufacturing methods are low volume and non-scalable. This has created a significant gap in the market and presents a tremendous growth opportunity for companies designed to seize it. This is where Pure Extracts steps in.

Pure Extracts provides high-grade extracts for functional mushroom products such as tinctures and soft gels with the plan to roll out beverage formulations, nasal and oral sprays, as well as psilocybin extracts by H1 2021 H1 2021 (http://ibn.fm/Jxe5m). Determined to leverage the momentum of the psychedelic and functional mushroom industries as one of the fastest-growing sectors in North America, Pure Extracts represents a unique value proposition in this expanding sector that requires extraction for product development.

With its proven expertise and EU Good Manufacturing Practices (“GMP”) designed facility for licensed extraction, Pure Extracts offers a clear competitive advantage. In a space where product purity is equal to product quality, the Company employs the most technologically advanced equipment required for full-spectrum CO2 extraction, a novel process for extracting the essence of the source material where the gas helps to extract oils of high-grade purity from the biomass. As the first of its kind, Pure Extracts is a nationally recognized brand that leverages five years of volatile plant molecule extraction experience and expertise in creating a number of successful CPG products with proven processes for delivering superior extracts.

Pure Extracts has ambitious plans to leverage its competitive advantage beyond North America and place itself as an extraction manufacturer of choice for functional and psychedelic medicine companies across the world. The company plans to apply for a Dealer’s License with Health Canada, which will enable it to produce extracts of the highest quality for clinical trials in an EU GMP environment, fueling its overseas expansion.

In addition, Pure Extracts’ location within the highly regarded Canadian regulatory framework allows for easy export from Canada to destinations across the world. This enables the Company to position itself as a natural international partner for psychedelic and functional product companies looking for pharmaceutical-grade psilocybin for their clinical trials and research.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts are available in the company’s newsroom at http://ibn.fm/Pure

• The company continues to make progress toward its mission to harness the power of technology to reinvent insurance
• Hospitality Liability coverage is an added layer of protection, allowing guests to feel safer and hotel and vacation rentals to lower their risk and claim ratios
• Further penetration of the vacation rental industry, which booked revenue of $57 million in 2019 and boasts a growth rate of 6.9%, provides the company with tremendous growth potential

InsuraGuest Technologies (TSX.V: ISGI), a company that’s disrupting the insurance landscape by utilizing its proprietary software platform to deliver digital insurance to multiple sectors, announced that its hospitality division, InsuraGuest Hospitality, recorded the highest month of revenue since inception, according to a company press release (http://ibn.fm/0oM4Z).

InsuraGuest Hospitality provides coverage for accidental property damage, theft of the guest’s personal property while residing at the vacation rental property, as well as accidental medical expenses and accidental death and dismemberment. InsuraGuest’s API integrates with approximately 70 different hotel property management systems, including Hilton -ONQ, Marriott Fosse, Marriott Full Service, Oracle Opera, Springer-Miller Systems, Agilysys and Lightspeed GPS.

The company continues to make progress toward its mission of harnessing the power of technology to reinvent insurance despite the significant challenges presented by COVID-19 and the resulting devastation the virus has levied upon the hospitality industry as a whole, the news release stated.

“Despite the COVID-19 pandemic, we are seeing an increase in hotel stays during July and as a result our hospitality division is having its best revenue month since we opened our doors,” said InsuraGuest CEO and Chairman, Douglas Anderson. “Our hotel members are creating safer environments for their guest’s visits, and they are seeing first-hand the value InsuraGuest brings by inserting our Hospitality Liability coverages as a layer of protection when a guest experiences an accident or theft. This allows the hotel to lower their risk ratio, lower their claim ratio, and remove their Med-Pay, thus helping them save money on their current General Liability policy.”

In July, the company partnered with Hostfully, a provider of end-to-end vacation rental property management software. InsuraGuest Hospitality Liability coverage can now be purchased by Hostfully’s client base of more than 2,500 vacation rental property managers. After opting in to InsuraGuest within Hostfully, clients can use the InsuraGuest Hospitality Liability coverage to address claims made by guests on a primary basis.

Hostfully is a complete property management platform that helps vacation rental property managers increase bookings and boost revenues. By streamlining the workflow and simplifying daily operational needs of vacation rental businesses, Hostfully empowers property managers with an affordable and easy-to-use solution. The company was named ‘Best All-Around Vacation Rental Software’ by VRMB Keystone Awards in 2019.

The growth potential in the vacation rental sector is encouraging for InsuraGuest’s investors. With over $57 billion in rental revenue in 2019 and a growth rate of 6.9%, the industry continues its growth as more and more people each year take advantage of the variety of benefits that vacations rentals offer (http://ibn.fm/SyPYv).

Europe’s hospitality market is more than double the market size in the United States, indicating room for significant growth potential in serving hotel and vacation rental guests with InsuraGuest’s insurance platform.

InsuraGuest Technologies is an insurtech company that is disrupting the insurance landscape by utilizing its proprietary software platform to deliver digital insurance to multiple verticals. The company aims to transform the way insurance is delivered with the revolutionary idea that insurance should be bought, not sold.

For more information, visit the company’s website at www.InsuraGuest.com.

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Agreement with leading drug-delivery company outlines plans to develop fast-acting, orally dissolving film for delivery of pharmaceutical-grade psilocybin
• Cybin CEO notes that systemic bioavailability of film is projected to be high
• Cybin focused on developing fungi-derived psychedelic, medicinal products to treat mental illness, other health conditions

Cybin Corp. announced that it has entered into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://ibn.fm/TZeVy). The agreement outlines plans for the two companies to develop a fast-acting, orally dissolving film for the delivery of pharmaceutical-grade psilocybin. “We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” said Cybin’s Chief Medical Officer Dr. Jukka Karjalainen. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high. In addition, the dose of psilocybin administered by an orally dissolving film is expected to be a fraction of what is required in oral capsules. Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.” Subject to receipt of all necessary regulatory approvals, the agreement allows both companies to capitalize on their strengths while partnering with a recognized expert in the space. Cybin is a mushroom life-sciences company focused on offering psychedelic and nutraceutical-based products. IntelGenx is recognized for its superior film technologies, including VersaFilm(R) and VetaFilm(TM), as well as its transdermal development and manufacturing capabilities. “Cybin’s intention with an orally dissolving psilocybin film is to bypass the digestive system, which will provide faster-acting relief for individuals with anxiety disorders who require more immediate symptom relief,” noted Cybin CEO Paul Glavine. According to IntelGenx CEO Dr. Horst G. Zerbe, the partnership “exemplifies both the versatility and clinical advantages of our VersaFilm(R) technology platform. In addition to offering patients a convenient method of administration, our technology offers superior drug bioavailability, which decreases both the amount of active pharmaceutical ingredient required per dose, as well as time to onset of action, which are paramount when treating distressing conditions such as anxiety. We are looking forward to working with Cybin to realize these potential benefits for patients struggling with mental health disorders.” Cybin operates in the functional-mushroom market with a goal to develop fungi-derived medicinal products to treat mental illness and other health conditions. The business model of this early-stage, life-sciences company includes two wholly owned core subsidiaries: Serenity Life Sciences, focusing on advancing research and development of psilocybin-based pharmaceutical products, and Natures Journey Inc., developing medicinal nonpsychedelic nutraceutical products. For more information about this company, please visit www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin